Pharmaceutical drugs – Scuba Dive Talks http://scubadivetalks.com/ Fri, 14 Jan 2022 21:55:38 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://scubadivetalks.com/wp-content/uploads/2021/07/scuba.png Pharmaceutical drugs – Scuba Dive Talks http://scubadivetalks.com/ 32 32 ‘Pharma Bro’ Shkreli banned for life from the pharmaceutical industry | Drug News https://scubadivetalks.com/pharma-bro-shkreli-banned-for-life-from-the-pharmaceutical-industry-drug-news/ Fri, 14 Jan 2022 20:41:56 +0000 https://scubadivetalks.com/pharma-bro-shkreli-banned-for-life-from-the-pharmaceutical-industry-drug-news/ Martin Shkreli was also ordered to pay $64 million in damages for monopolizing the market for a life-saving drug. Through Erik Larson and Sebastian TongBloomberg Posted Jan 14, 2022Jan 14, 2022 Martin Shkreli, the convicted ‘Pharma Bro’ who was brought down by a drug price scandal in 2015, has been ordered to pay $64 million […]]]>

Martin Shkreli was also ordered to pay $64 million in damages for monopolizing the market for a life-saving drug.

Through Bloomberg

Martin Shkreli, the convicted ‘Pharma Bro’ who was brought down by a drug price scandal in 2015, has been ordered to pay $64 million in damages for monopolizing the market for a life-saving drug.

Shkreli, the former CEO of Vyera Pharmaceuticals LLC, was also banned for life from the pharmaceutical industry in the antitrust ruling handed down Friday by U.S. District Judge Denise Cote in Manhattan.

New York Attorney General Letitia James, who has sued six other states and the U.S. Federal Trade Commission, said in a statement that Shkreli was motivated by “envy” and “greed.” when he decided to “illegally raise the price of a life-saving drug while the lives of Americans were at stake.”

Shkreli is already serving a seven-year sentence for securities fraud committed while running two hedge funds, although the same drug – Daraprim – is at the center of both cases.

Vyera, then known as Turing Pharmaceuticals, was launched by Shkreli in 2015. It was then that it acquired Daraprim, a once-affordable anti-infective used to treat a sometimes deadly parasitic infection, from the only existing vendor . Shkreli then increased the price by $17.50 to $750 per tablet.

Cote discovered that Shkreli made illegal deals with generic drug makers to delay the introduction of cheaper versions of the drug after raising the price.

“Shkreli does not dispute that he intended to prevent generic pharmaceutical companies from launching competing products that would threaten the price of Daraprim,” the judge wrote. “The plaintiffs have shown that the restraints put in place by Vyera have succeeded in doing just that.”

Last month, Vyera and another former chief executive, Kevin Mulleady, agreed to pay up to $40 million to resolve their involvement in the federal antitrust lawsuit filed by New York and other states.

(Updates with dispute details)

]]>
Purdue Pharma Opioid Settlement Rejected by Judge | MedTruth – Safety of Prescription Drugs and Medical Devices https://scubadivetalks.com/purdue-pharma-opioid-settlement-rejected-by-judge-medtruth-safety-of-prescription-drugs-and-medical-devices/ Wed, 12 Jan 2022 22:21:39 +0000 https://scubadivetalks.com/purdue-pharma-opioid-settlement-rejected-by-judge-medtruth-safety-of-prescription-drugs-and-medical-devices/ By the editors of MedTruth U.S. District Court Judge Colleen McMahon issued a ruling in New York on December 16 that rejected the bankruptcy settlement plan that would have resolved thousands of opioid epidemic lawsuits filed by states and municipalities against the manufacturer of Oxycontin, Purdue Pharma. McMahon justified his rejection of the plan because […]]]>

U.S. District Court Judge Colleen McMahon issued a ruling in New York on December 16 that rejected the bankruptcy settlement plan that would have resolved thousands of opioid epidemic lawsuits filed by states and municipalities against the manufacturer of Oxycontin, Purdue Pharma.

McMahon justified his rejection of the plan because of the liability protections that would be given to individual members of the Sackler family.

Based in Ohio WTVA reported that supporters of the plan would likely appeal McMahon’s decision.

Facing thousands of lawsuits for its alleged role in contributing to a national health crisis linked to more than 500,000 deaths over the past two decades, Purdue filed for bankruptcy protection in 2019.

Under Chapter 11 bankruptcy protection, Purdue would still be allowed to operate, without any members of the Sackler family, owners of the drug company since 1952.

Under the plan, proceeds from oxycontin sales would be directed to opioid addiction reduction programs. If the bankruptcy settlement is successfully appealed and ultimately approved, the new Purdue would also develop anti-addiction drugs at little or no cost to the public.

Additionally, the settlement also reportedly saw the Sacklers lose $4.5 billion of their estimated net worth of $11 billion. Municipalities and state governments would be required to allocate their individual share of settlement funds to opioid addiction programs in their respective areas.

The majority of U.S. states, municipalities, Native American tribes and individuals who filed opioid lawsuits against Purdue agreed in principle to the terms of the settlement.

Judge McMahon’s court initially accepted the settlement in September 2021. Some plaintiffs, including attorneys general from eight states and representatives from various territories, opposed the plan and asked McMahon to reject the settlement due to the lack of liability that members of the Sacklers would face and the legal protections afforded to them.

In the decade before Purdue’s bankruptcy, members of the Sacklers transferred more than $10 billion from the company’s coffers to other accounts. Judge McMahon told a hearing that she wanted to know if the financial moves were premeditated to protect the Sacklers in the event of a declaration of bankruptcy.

]]>
Drug shortage likely due to dollar crisis https://scubadivetalks.com/drug-shortage-likely-due-to-dollar-crisis/ Tue, 11 Jan 2022 02:22:00 +0000 https://scubadivetalks.com/drug-shortage-likely-due-to-dollar-crisis/ COLOMBO (News 1er): Many problems have arisen regarding the importation of pharmaceutical drugs in the face of the dollar crisis prevailing in Sri Lanka, which could lead to a shortage of life-saving drugs in the future, medical professionals have warned from the country. “At present, given the non-issuance of letters of credit under the Department […]]]>

COLOMBO (News 1er): Many problems have arisen regarding the importation of pharmaceutical drugs in the face of the dollar crisis prevailing in Sri Lanka, which could lead to a shortage of life-saving drugs in the future, medical professionals have warned from the country.

“At present, given the non-issuance of letters of credit under the Department of Health and the State Departments of Health, there is a looming crisis of a shortage of nearly 80 drugs in the country this entire year, ”Ravi Kumudesh, the President of the Federation of Complementary Medical Services told News 1st.

According to Kumudesh, letters of credit have not yet been issued for the import of nearly 80 pharmaceutical drugs, including for the treatment of cancer, heart disease, pediatric drugs and chronic kidney disease, among others.

“Drug purchase orders are placed a year in advance, which means letters of credit for drugs in January should have been issued in August or September of last year. Buying and importing drugs takes about 04 months, ”he noted.

During this time,

Responding to questions from reporters regarding the non-issuance of letters of credit for the purchase of drugs, Deputy Director General of Health Services, Dr Hemantha Herath said: “Logically, the impact of non-issuance of letters of credit could affect the importation of drugs. “

However, he noted that since priority is given to importing essential items, a shortage of drugs could be avoided.

]]>
Aspergillosis Drugs Market 2022 by Types, Applications and Major Key Players – Janssen Pharmaceutica, Honz Pharmaceutical, Lepu Pharmaceuticals, SRS Pharmaceuticals Pvt. Ltd, Merck https://scubadivetalks.com/aspergillosis-drugs-market-2022-by-types-applications-and-major-key-players-janssen-pharmaceutica-honz-pharmaceutical-lepu-pharmaceuticals-srs-pharmaceuticals-pvt-ltd-merck/ Sun, 09 Jan 2022 06:12:11 +0000 https://scubadivetalks.com/aspergillosis-drugs-market-2022-by-types-applications-and-major-key-players-janssen-pharmaceutica-honz-pharmaceutical-lepu-pharmaceuticals-srs-pharmaceuticals-pvt-ltd-merck/ The Aspergillosis Drugs Market Report is the most important research for those looking for comprehensive information on the Aspergillosis Drugs Markets. The report covers all the information on the global and regional markets including past and future trends for market demand, size, trade, supply, competitors and prices as well as information of global major vendors. […]]]>

The Aspergillosis Drugs Market Report is the most important research for those looking for comprehensive information on the Aspergillosis Drugs Markets. The report covers all the information on the global and regional markets including past and future trends for market demand, size, trade, supply, competitors and prices as well as information of global major vendors. . The report also provides a comprehensive overview of the Aspergillosis Drugs markets; including top players or vendors, app, type, sharing, and the latest market trends.

In-depth market analysis is combined with precise forecasts and projections in this Aspergillosis Drugs Market report resulting in comprehensive research solutions that provide absolute clarity to the industry for strategic decision making. Raw market data is collected and analyzed on a large scale. Data is also collected from a number of publications in our archives, as well as a number of well-known paid databases. The data in this Aspergillosis Drugs market report has been gathered from raw material vendors, dealers, and customers to get a complete understanding of the industry; therefore, this report is extremely helpful to the buyer.

Aspergillosis Drugs Market: Competition Landscape

The Aspergillosis Drugs market report includes information on product launches, sustainability, and outlook for major vendors, including: (Janssen Pharmaceutica, Honz Pharmaceutical, Lepu Pharmaceuticals, SRS Pharmaceuticals Pvt. Ltd, Merck, United Biotech (P) Limited, Basilea Pharmaceutica, Cardinal Health, Taj Pharma, Natco Pharma, Astellas, Tianjin Lisheng Pharmaceutical, Huasun Pharmaceutical, Luoxin Biotechnology, GSK (GlaxoSmithKline), Pfizer Deutschland GmbH)

Click the Link for Free Sample Copy of Report @ https://crediblemarkets.com/sample-request/aspergillosis-drugs-market-631763?utm_source=Komal&utm_medium=SatPR

Aspergillosis Drugs Market: Segmentation

The Aspergillosis Drugs market is split by type and by application for the period 2022-2028, the growth among the segments provides accurate devices and sales forecast by type and by application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

By types:

Caspofungin Acetate for Injection
Itraconazole capsules
Voriconazole tablets

By applications:

Invasive aspergillosis
Allergic aspergillosis
Allergic bronchopulmonary aspergillosis

Aspergillosis Drugs Market: Regional Analysis

All the regional segmentation has been studied on the basis of recent and future trends, and the market is forecast throughout the forecast period. The countries covered in the regional analysis of the Global Aspergillosis Drugs Market report are United States, Canada, and Mexico in North America, Germany, France, United Kingdom, Russia, in Italy, Spain, Turkey, the Netherlands, Switzerland, Belgium and the rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, Korea South, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) ) being part of the Middle East and Africa (MEA), and Argentina, Brazil and the rest of South America being part of South America.

Direct purchase this market research report now @ https://crediblemarkets.com/reports/purchase/aspergillosis-drugs-market-631763?license_type=single_user;utm_source=Komal&utm_medium=SatPR

Main points covered by the table of contents:

To present: Besides a detailed overview of the global Aspergillosis Drugs market, this segment provides an overview of the report to give insight into the nature and substance of the review study.

Analysis of the strategies of the main players: Market players can use this analysis to gain competitive advantage over their competitors in the Aspergillosis Drugs market.

Study on the main market trends: This part of the report offers a more meaningful assessment of recent and future examples of the market.

Market Forecast: Buyers of the report will tackle accurate and approved valuations of all market sizes in terms of value and volume. The report further gives usage, creation, offerings, and different conjectures for the Aspergillosis Drugs market.

Analysis of local growth: All critical regions and countries have been covered in the report. Neighborhood review will help uplift players to exploit rejected common business areas, prepare express philosophies for target regions, and consider improving each regional market.

Segmental analysis: The report gives precise and solid conjectures on a part of the pie for important parts of the Aspergillosis Drugs Market. Market members can use this review to pinpoint key interests in key development pockets of the market.

Do you have a specific question or requirement? Ask Our Industry Expert @ https://crediblemarkets.com/enquire-request/aspergillosis-drugs-market-631763?utm_source=Komal&utm_medium=SatPR

Key questions answered in the report:

  • What will be the pace of development of the Aspergillosis Drugs market?
  • What are the key factors driving the global Aspergillosis Drugs market?
  • Who are the main manufacturers in the market?
  • What are the market openings, the market risks and the main lines of the market?
  • What are the sales, revenue, and price analyzes of the major manufacturers of the Aspergillosis Drugs market?
  • Who are the distributors, traders and resellers of the Aspergillosis Drugs market?
  • What are the Aspergillosis Drugs market opportunities and threats faced by the vendors of the global Aspergillosis Drugs industries?
  • What is Offerings, Revenue, and Value Review by Types and Uses in the Market?
  • What are Transactions, Revenue, and Value Review by Business Line?

About Us

Credible Markets is a new age market research company with a firm grip on the pulse of global markets. Credible Markets has become a reliable source for the market research needs of companies in a rapid period of time. We have worked with leading market information publishers and our reporting pool coverage spans all key industry verticals and thousands of micro markets. The massive repository allows our clients to choose from recently published reports from a range of publishers who also provide in-depth regional and national analysis. Plus, pre-booked research reports are some of our best deals.

The collection of market information reports is regularly updated to provide visitors with easy access to the most recent market information. We provide round-the-clock support to help you reuse search parameters and thus benefit from a full range of reserved reports. After all, it’s all about helping you make an informed strategic decision about purchasing the right report that meets all of your market research demands.

Contact us

Credible market analyzes
99 Wall Street 2124 New York, NY 10005
E-mail: [email protected]

]]>
CMS seeks to pass Part D price reductions to beneficiaries https://scubadivetalks.com/cms-seeks-to-pass-part-d-price-reductions-to-beneficiaries/ Fri, 07 Jan 2022 17:01:36 +0000 https://scubadivetalks.com/cms-seeks-to-pass-part-d-price-reductions-to-beneficiaries/ CMS on Thursday proposed developing rules that would shift pharmaceutical price concessions to beneficiaries of Medicare Part D plans and make the medical wastage ratio in Medicare Advantage plans more robust. CMS on Thursday proposed draft rules aimed at Medicare Advantage (MA) transparency, including improvements for beneficiaries who are doubly eligible, and changes to Part […]]]>

CMS on Thursday proposed developing rules that would shift pharmaceutical price concessions to beneficiaries of Medicare Part D plans and make the medical wastage ratio in Medicare Advantage plans more robust.

CMS on Thursday proposed draft rules aimed at Medicare Advantage (MA) transparency, including improvements for beneficiaries who are doubly eligible, and changes to Part D, including the transfer of any price concessions received. from pharmaceutical companies to beneficiaries at the pharmacy counter.

“We are committed to ensuring that older Americans and people with disabilities served by the Medicare program have access to quality, affordable health care, including prescription drugs and therapies,” CMS Administrator said , Chiquita Brooks-LaSure, in a statement. “The actions proposed today follow our guiding principles by improving health equity and improving access to prescription drugs.

In a fact sheet, CMS wants Part D plans that have agreements with certain pharmacies, where they pay less for drugs if parameters are not met, to share the savings with beneficiaries by applying those savings to the negotiated price of the drug.

The agency is also proposing to redefine the negotiated price as the lowest eligible payment at a pharmacy, effective January 1, 2023.

In the proposed rule, CMS said Plan D costs to beneficiaries would be reduced by 2%, or $ 21.3 billion over 10 years. However, the plan would cost the government $ 40 billion during this period due to the increase in direct grants and bonus payments to low incomes, which is a 3% increase. Drugmakers would save about $ 14.6 billion, CMS said.

CMS said the move “would reduce out-of-pocket expenses for Medicare Part D beneficiaries and improve price transparency and market competition under the Part D program.”

For beneficiaries eligible for both Medicare and Medicaid, CMS seeks to improve the information they receive in an effort to achieve health equity and reduce health disparities.

The proposed rule would require MA organizations with Dual Qualifying Special Needs Plans (D-SNPs) to establish, maintain and consult one or more registered advisory committees to include the voices of those beneficiaries, who tend to be low-income. and have more chronic problems. diseases. The proposal would streamline complaints and appeals processes in some D-SNPs, simplify information on access to services, and change the cost-sharing of MA to improve payments to providers serving this population.

Beneficiaries should be asked about their barriers to accessing care through standardized questions in the required health risk assessments on housing instability, food insecurity and transportation. CMS would strengthen oversight of third party marketing organizations that act, directly or indirectly, on behalf of MA organizations and Party D sponsors by demanding free translation services.

In addition, requests for new or extended MA plans must show that they have a sufficient network of contracted suppliers. If previous performance was poor, MA’s plans could not expand.

Another part of the rule would increase what MA and Party D must report on their Medical Loss Report (MLR). MLR is the share of premiums spent on medical care; currently, plans must meet an MLR of 85%.

The proposal would require reporting the underlying cost and revenue information needed to calculate and verify the MLR percentage and payout amount, which was the case from 2014 to 2017.

Additionally, if the rule is passed, plans should include amounts spent to provide additional benefits (dental, vision, hearing, transportation, and meals) that are not provided in traditional fee-for-service health insurance. .

]]>
Antifolate Compounds Drugs Market Size, Scope, Forecast to 2029 https://scubadivetalks.com/antifolate-compounds-drugs-market-size-scope-forecast-to-2029/ Thu, 06 Jan 2022 01:33:13 +0000 https://scubadivetalks.com/antifolate-compounds-drugs-market-size-scope-forecast-to-2029/ New Jersey, United States, – The latest report published by Verified Market Reports shows that the Antifolate Compounds Drugs Market should experience a sustained pace in the years to come. Analysts looked at market drivers, restrictions, risks and openings in the global market. The Drugs for Antifolate Compounds report shows the likely direction of the […]]]>

New Jersey, United States, – The latest report published by Verified Market Reports shows that the Antifolate Compounds Drugs Market should experience a sustained pace in the years to come. Analysts looked at market drivers, restrictions, risks and openings in the global market. The Drugs for Antifolate Compounds report shows the likely direction of the market in the coming years along with its estimates. An in-depth study aims to understand the market price. By analyzing the competitive landscape, the report’s authors have made a brilliant effort to help readers understand the key business tactics used by large companies to keep the market sustainable.

The report comprises the profiles of almost all the significant players in the Drugs for Antifolate Compounds market. The company profile section offers valuable analysis of strengths and weaknesses, business developments, recent advancements, mergers and acquisitions, expansion plans, global footprint, market presence and Product portfolios of the main market players. This information can be used by players and other market participants to maximize their profitability and streamline their business strategies. Our competitive analysis also includes key information to help new entrants to identify market entry barriers and measure the level of competitiveness in the Antifolate Compounds Drugs market.

Get sample full PDF copy of report: (including full table of contents, list of tables and figures, graph) @ https://www.verifiedmarketreports.com/download-sample/?rid=126158

Key Players Mentioned in the Antifolate Compounds Drugs Market research report:

Alimta, IPCA Laboratories, Bristol-Myers, Baoding Zhongbao Chemical, GlaxoSmithKline, Eli Lilly, Mylan Labs, Kissei Pharmaceutical, IPCA Laboratories, Cipla, Genentech

Antifolate Compounds Drugs Market Segmentation:

By Product Type, the market is majorly split into:

• Antineoplastic and immunosuppressive
• Antineoplastic
• Antimalarial
• Antiprotozoal
• Broad spectrum antimicrobial

By application, this report covers the following segments:

• Methotrexate
• Pemetrexed
• Proguanil
• Pyrimethamine
• Trimethoprim

The global Antifolate Compounds Drugs market is segmented on the basis of product, type, services, and technology. All of these segments were studied individually. The detailed investigation helps to assess the factors influencing the Drugs for Antifolate Compounds market. Experts analyzed the nature of development, investments in research and development, changing consumption patterns and the growing number of applications. In addition, analysts have also assessed the economic developments of the Drugs for Antifolate Compounds market which is likely to affect its price.

The regional analysis section of the report enables players to focus on high growth regions and countries which could help them expand their presence in the Antifolate Compounds Drugs market. Besides expanding their footprint in the Antifolate Compounds Drugs market, the regional analysis helps players to increase their sales while having a better understanding of customer behavior in specific regions and countries. The report provides the CAGR, revenue, production, consumption, and other important statistics and figures related to the global and regional markets. It shows how different types, applications, and regional segments are advanced in the Drugs for Antifolate Compounds market in terms of growth.

Get a discount on purchasing this report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=126158

Scope of the Antifolate Compounds Drugs Market Report

ATTRIBUTES DETAILS
ESTIMATED YEAR 2022
YEAR OF REFERENCE 2021
PLANNED YEAR 2029
HISTORICAL YEAR 2020
UNITY Value (million USD / billion)
COVERED SEGMENTS Types, applications, end users, etc.
REPORT COVER Revenue forecast, company ranking, competitive landscape, growth factors and trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free customization of the report (equivalent to 4 working days for analysts) with purchase. Add or change the scope of country, region and segment.

Geographic segment covered in the report:

The Drugs for Antifolate Compounds report provides information about the market area, which is further further subdivided into sub-regions and countries / regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country and sub-region during the estimated period.

• North America (United States and Canada)
• Europe (UK, Germany, France and rest of Europe)
• Asia-Pacific (China, Japan, India and the rest of the Asia-Pacific region)
• Latin America (Brazil, Mexico and the rest of Latin America)
• Middle East and Africa (GCC and rest of Middle East and Africa)

Key questions answered in the report:

1. Who are the top five players in the Antifolate Compounds Drugs market?

2. How will the Antifolate Compounds Drugs market evolve over the next five years?

3. What product and application will capture the lion’s share of the Antifolate Compounds Drugs market?

4. What are the drivers and restraints of the Antifolate Compounds Drugs market?

5. Which regional market will show the most growth?

6. What will be the CAGR and size of the Antifolate Compounds Drugs market throughout the forecast period?

For more information or a query or a personalization before purchasing, visit @ https://www.verifiedmarketreports.com/product/global-drugs-for-antifolate-compounds-market-report-2019-competitive-landscape-trends-and-opportunities/

Visualize the Antifolate Compounds Drugs Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for narrative storytelling for this market. VMI offers in-depth forecasting trends and accurate insight into over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a holistic overview and global competitive landscape with regard to region, country and segment, and key players in your market. Present your market report and findings with a built-in presentation function, saving over 70% of your time and resources for investor arguments, sales and marketing, R&D and product development. VMI enables data delivery in interactive Excel and PDF formats with over 15+ key market indicators for your market.

Visualize the Drug Market for Antifolate Compounds Using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

Main trend reports

Global Construction Spending Market Size and Forecast

Global Agency Management Software Market Size and Forecast

Global Antifolate Compounds Drugs Market Size and Forecast

Global Oximeter Market Size and Forecast

Global cisapride market size and forecast

Global Pediatric Physiotherapy Market Size and Forecast

Global Foreign Body Forceps Market Size and Forecast

Pradaxa Global Market Size and Forecast

Global Ct Contrast Injectors Market Size and Forecast

Global Professional Employers’ Organizations (PEOs) Market Size and Forecast

About us: verified market reports

Verified Market Reports is a leading global research and advisory firm serving more than 5,000 clients around the world. We provide advanced analytical research solutions while delivering insightful research studies.

We also offer insight into the strategic and growth analyzes and data needed to achieve business goals and critical revenue decisions.

Our 250 analysts and SMEs offer a high level of expertise in data collection and governance using industry techniques to collect and analyze data on more than 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Our research spans a multitude of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage, and more. Having served numerous Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

E-mail: [email protected]

Website: – https://www.verifiedmarketreports.com/

]]>
Increase seen in life-threatening squeezed pills https://scubadivetalks.com/increase-seen-in-life-threatening-squeezed-pills/ Tue, 04 Jan 2022 00:10:00 +0000 https://scubadivetalks.com/increase-seen-in-life-threatening-squeezed-pills/ LAWRENCE COUNTY, Ohio (WSAZ) – When it comes to buying pills and other forms of illicit drugs, Jessica Pennington, who is a recovering addict, says the exchange is not like it used to be . “You just don’t know what you’re getting anymore,” Pennington said. The uncertainty arises from an increase in the number of […]]]>

LAWRENCE COUNTY, Ohio (WSAZ) – When it comes to buying pills and other forms of illicit drugs, Jessica Pennington, who is a recovering addict, says the exchange is not like it used to be .

“You just don’t know what you’re getting anymore,” Pennington said.

The uncertainty arises from an increase in the number of substances like fentanyl that are disguised as other drugs.

“Now what the drug dealers do is make it look like someone is getting a pharmaceutical grade oxycodone, and pharmaceutical grade oxycodone won’t kill you if you take one … but a pill.” fentanyl can kill you if you take one, ”Lawrence said County Attorney Brigham Anderson.

Anderson says they can look like regular pills, like Xanax for example. There is no distinguishing feature to tell whether a squeezed pill contains fentanyl or not, so Anderson says the best way to make sure you’re getting safe drugs is through the pharmacy, ”Anderson said.

“These pills containing fentanyl will never come from a drugstore. They are made by man; they are made by drug dealers. We recently had a drug seizure in the Rome Township area of ​​Lawrence County where three people from Detroit had two apartments and they had a real press where they would take substances and squeeze them into pill form. This has seen a huge increase in our fatal overdoses, ”Anderson said.

It’s a deadly problem that has escalated in recent months, causing concern among people like Pennington who know firsthand how difficult they are to identify.

“You really can’t tell a difference, but if you move them around or leave them lying around in your pocket or something like that, they’ll start to fall apart because they’re in a rush. They aren’t perfect like the drugstore, but they look the same to them, ”Pennington said.

Anderson says that in the effort to get these squeezed pills off the streets, the county drug task force is increasing its patrols and doing more undercover work.

Copyright 2022 WSAZ. All rights reserved.

]]>
Heavy hydrogen stabilizes drugs, study finds https://scubadivetalks.com/heavy-hydrogen-stabilizes-drugs-study-finds/ Sun, 02 Jan 2022 05:45:00 +0000 https://scubadivetalks.com/heavy-hydrogen-stabilizes-drugs-study-finds/ ANI | Update: 02 Jan 2022 11:15 AM STI Bonn [Germany]Jan. 2 (ANI): A team of researchers has found a method that specifically introduces the hydrogen heavier “brother” deuterium into many different molecules. Drugs produced using this method may be effective for longer and may be taken in lower doses or less frequently.The study was […]]]>



ANI |
Update:
02 Jan 2022 11:15 AM STI

Bonn [Germany]Jan. 2 (ANI): A team of researchers has found a method that specifically introduces the hydrogen heavier “brother” deuterium into many different molecules. Drugs produced using this method may be effective for longer and may be taken in lower doses or less frequently.
The study was published in the “Angewandte Chemie International Edition Journal”.
Hydrogen (abbreviated “H”) is the lightest of all the elements. It usually consists of only one positively charged proton and one negatively charged electron and is also referred to as protium in this form. But there are also two heavier hydrogen isotopes, deuterium and tritium. The deuterium nucleus contains a neutron in addition to the proton, in the case of tritium there are even two. Both are very rare; tritium is also – unlike deuterium and protium – radioactive.
Deuterium has been at the center of pharmaceutical research for a few years because it can ensure that drugs break down 5, 10, or even 50 times slower.
“We call it the kinetic isotope effect,” explained Prof. Andreas Gansauer from the Kekule Institute for Organic Chemistry and Biochemistry at the University of Bonn (Germany).
The reason is that many reactions, including the degradation of active substances, do not occur spontaneously. They first need a slight “push”, the energy of activation. It’s a bit like driving a miniature car up a hill: this too only works if the car has enough momentum.
“If you replace the hydrogen with deuterium, the activation energy usually increases somewhat. As a result, the reactions are slower. This also applies to the metabolism of pharmaceuticals in the liver,” Gansauer said.

This means that the introduction of deuterium instead of protium in drugs makes them have a longer effect. They can therefore be taken in lower doses or less frequently. However, deuterium is rare and therefore relatively expensive. Therefore, deuterium should ideally only be introduced at points where metabolization predominantly occurs. This is where the new process comes in.
It is based on a class of substrates called epoxies, which can now be produced almost at will in different ways. These groups can be visualized as a kind of “triangle” in which two corners are formed by carbon atoms and the third by an oxygen atom. Such three-link rings are put under great tension, which means that they easily tear on one side. Epoxies therefore store energy like a stretched spring, which can then be used for certain reactions.
“We introduced epoxides into different test molecules, then opened the strained ring with our catalyst. It contains a titanium atom to which deuterium is attached,” Gansauer explained.
To put it figuratively, when the epoxy ring is opened, two reactive ends are created. The catalyst binds to one of them, which then transfers the deuterium to the remaining free end in a second step.
“This allows us to introduce a deuterium atom in one place and with a very specific and desired spatial orientation,” Gansauer said. He is a member of the transdisciplinary research area “Building Blocks of Matter and Fundamental Interactions” (TRA Matter) at the University of Bonn.
Another advantage of the method is that for many complex molecules, there are two different ways of binding which mirror each other. The new process can be used to create almost exclusively one of the two shapes.
“As the compounds of mirror image molecules are very difficult to separate and, moreover, they often have different properties in the human body, such stereoselectivity is very important,” commented Gansauer.
The developed method has been used, for example, to produce deuterated precursors of the analgesic ibuprofen and the antidepressant venlafaxine. The authors are confident that it will be applied to many other pharmaceuticals in the future. (ANI)

]]>
Vertex Pharmaceuticals stock: bullish against bearish https://scubadivetalks.com/vertex-pharmaceuticals-stock-bullish-against-bearish/ Fri, 31 Dec 2021 12:03:00 +0000 https://scubadivetalks.com/vertex-pharmaceuticals-stock-bullish-against-bearish/ Vertex pharmaceutical (NASDAQ: VRTX) was a big disappointment for investors in 2021. While the S&P 500 index climbed nearly 30%, shares of Vertex are down 5%. However, investors are much more focused on the direction a stock might take than it has been in the past. But there are often different views on what the […]]]>

Vertex pharmaceutical (NASDAQ: VRTX) was a big disappointment for investors in 2021. While the S&P 500 index climbed nearly 30%, shares of Vertex are down 5%.

However, investors are much more focused on the direction a stock might take than it has been in the past. But there are often different views on what the future holds for a given title. This is certainly the case with Vertex. Here are both bullish and bearish arguments for biotech stocks.

Image source: Getty Images.

Potential game changers on the way

Keith Speights: What I like most about Vertex is that the company is not resting on its laurels. The large drugmaker has a monopoly on cystic fibrosis (CF) treatment. And he’s using the money generated by his hugely successful CF franchise to invest in developing game-changing therapies.

top and CRISPR Therapeutics hope to file regulatory approvals for CTX001 by the end of 2022 in the beta thalassemia and sickle cell indications. CTX001 could be the first CRISPR gene editing therapy on the market. It doesn’t just treat beta thalassemia and sickle cell disease; an infusion of CTX001 has the potential to cure disease in some patients.

Meanwhile, Vertex has another program developed in-house that could also allow the company to grow beyond CF. On December 1, he announced the promising results of a Phase 2 study evaluating VX-147 for the treatment of the rare kidney disease, focal segmental glomerulosclerosis (FSGS) mediated by APOL1. The company plans to make VX-147 pivotal tests in early 2022 focusing on APOL1-mediated kidney disease. Over 100,000 patients in the United States and Europe suffer from this genetic disease, which represents a larger potential market than cystic fibrosis.

Vertex also reported encouraging data in October for VX-880 in the treatment of type 1 diabetes. The company continues to evaluate VX-880 in phase 1/2 testing. It also plans to file an Investigational New Drug (IND) application in 2022 to begin clinical testing of cell therapy that could eliminate the need for immunosuppressants. Vertex may well have a cure for type 1 diabetes.

Be bearish on Vertex if you are bullish in the market

Taylor Carmichael: I think Vertex Pharmaceuticals is a good stock to own. Along with its drug Kalydeco, it has been the dominant name in cystic fibrosis (CF) for years. The DrugPatentWatch website estimates that it won’t face generic competition until 2029. This is one of the biggest threats for a pharmaceutical company with a dominant drug: When will it fall off the patent cliff? Vertex investors have nearly a decade to plan ahead. And with the arrival of biotech’s next-generation CF molecule, Trikafta, this loss of Kalydeco revenue could in fact be a non-event. And the Trikafta patent is valid until 2037.

As you can see, I’m not particularly bearish on the stock. Pharmaceutical companies with a dominant franchise like Vertex have good profit margins (30%), and the company is still viewed as a growth stock with revenue growth of 29%. What not to like?

Well, I think every stock you buy should be compared to an index fund, such as the SPDR S&P 500 ETF. And remember: when we talk about “market”, we are talking about world champions like Apple, Amazon, Microsoft, etc. So while Vertex is a fantastic biotech company, I think it will likely be underperforming any high tech index fund over the next decade.

VRTX Chart

VRTX data by YCharts.

So in isolation I like Vertex. The company has a strong monopoly in cystic fibrosis and could surprise on the upside with positive results from trials of its pain relievers, diabetes drug or perhaps sickle cell drug, all of which are in trials early clinics. These drugs are several years away from possible Food and Drug Administration approval.

To me, investing in Vertex is really kind of a macro question. Where do you think the stock market will go over the next five to ten years? If you are a bull, an S&P index fund is probably a safer and more successful bet. But if you are bearish in the stock market, worried about a technology wreck or rising interest rates, then Vertex is the action for you.

CF patients will buy the company’s drugs, even as the economy crumbles all around us. Nervous Nellies should jump on Vertex – that’s one of the safest stocks, in my opinion. But it is likely to lag behind the market over time.

Is Vertex an action for you?

Individual investors will have to determine for themselves whether the bullish or bearish arguments for Vertex are stronger. The stock could have several catalysts on the way. But, as Taylor mentioned, there is a possibility that other stocks (and even index funds) will outperform it.

10 stocks we prefer at Vertex Pharmaceuticals
When our award-winning team of analysts have stock advice, it can pay off to listen. After all, the newsletter they’ve been running for over a decade, Motley Fool Equity Advisor, has tripled the market. *

They just revealed what they think are the top ten stocks investors can buy right now … and Vertex Pharmaceuticals was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* Returns of the portfolio advisor as of December 16, 2021

Teresa Kersten, an employee of LinkedIn, a subsidiary of Microsoft, is a member of the board of directors of The Motley Fool. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of the board of directors of The Motley Fool. Keith Speights owns Amazon, Apple, Microsoft, and Vertex Pharmaceuticals. Taylor Carmichael owns Amazon and Apple. The Motley Fool owns and recommends Amazon, Apple, CRISPR Therapeutics, Microsoft, and Vertex Pharmaceuticals. The Motley Fool recommends the following options: January 2022 long calls at $ 1,920 on Amazon, March 2023 long calls at $ 120 on Apple, January 2022 short calls at $ 1,940 on Amazon, and short calls March 2023 at $ 130 $ on Apple. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

]]>
Sun Pharma Expected to Shine on Domestic Outlook, US Sales Gain Speed https://scubadivetalks.com/sun-pharma-expected-to-shine-on-domestic-outlook-us-sales-gain-speed/ Wed, 29 Dec 2021 18:44:50 +0000 https://scubadivetalks.com/sun-pharma-expected-to-shine-on-domestic-outlook-us-sales-gain-speed/ Shares of India’s largest drugmaker Sun Pharmaceutical Industries (Sun Pharma) were the biggest gainers among Sensex stocks, rising 2.9% on Wednesday. The stock has extended its gains over the past four trading sessions to around 7 percent. The upward trend is based on expectations that complex drug approvals in the United States, the outperformance of […]]]>

Shares of India’s largest drugmaker Sun Pharmaceutical Industries (Sun Pharma) were the biggest gainers among Sensex stocks, rising 2.9% on Wednesday. The stock has extended its gains over the past four trading sessions to around 7 percent.

The upward trend is based on expectations that complex drug approvals in the United States, the outperformance of domestic formulations and the gradual gains of anti-Covid launches in India will increase its revenue. The decision to set up a manufacturing plant in Andhra Pradesh (AP) is also viewed positively by the streets. While …

MONTHLY STAR

Digital Business Standard

Business Standard Digital monthly subscription

Full access to premium product

Convenient – Pay as you go

Pay using Amex / Master / VISA credit cards and VISA debit cards only

Automatically renewed (subject to authorization from your card issuer)

Cancel any time in the future

Requires personal information

What do you get?

ON STANDARD COMMERCIAL DIGITAL

  • Unlimited access to all content on any device via browser or app.
  • Exclusive content, features, opinions and reviews – handpicked by our editors, just for you.
  • Pick 5 of your favorite companies. Receive a daily email with all updates on them.
  • Follow the industry of your choice with a daily industry-specific newsletter.
  • Stay on top of your investments. Track the prices of stocks in your portfolio.
  • 18 years of archival data.

REMARK :

  • The product is a monthly automatic renewal product.
  • Cancellation policy: You can cancel at any time in the future without giving a reason, but 48 hours before your card is charged for renewal. We do not offer refunds.
  • To cancel, communicate from your registered email id and send the email with the cancellation request to assist@bsmail.in. Include your contact number for quick action. Requests sent by post to any other identifier will not be recognized or processed.

ANNUAL SMART

Digital Business Standard
Subscribe now and get 12 months free

Business Standard Premium Digital – 12 Months + 12 Months Free

Subscribe for 12 months and get 12 months free.

Unique and transparent registration to Business Standard Digital

Convenient – Payment once a year

Pay using an instrument of your choice – all credit and debit cards, Net Banking, payment wallets and UPI

Exclusive invitation to certain Business Standard events

What you get

ON STANDARD COMMERCIAL DIGITAL

  • Unlimited access to all content on any device via browser or app.
  • Exclusive content, features, opinions and reviews – handpicked by our editors, just for you.
  • Pick 5 of your favorite companies. Receive a daily email with all updates on them.
  • Follow the industry of your choice with a daily industry-specific newsletter.
  • Stay on top of your investments. Track the prices of stocks in your portfolio.

REMARK :

  • The monthly term product is an automatic renewal based product. Once subscribed, subject to the authorization of your card issuer, we will automatically debit your card / payment instrument each month and renew your subscription.
  • In the annual term product, we offer both a product based on automatic renewal and a product not based on automatic renewal.
  • We do not reimburse.
  • No questions asked Cancellation policy.
  • You can cancel future renewals at any time, including immediately after subscription, but 48 hours before the next renewal date.
  • Subject to the above, cancel yourself by visiting the “Manage my account” section after logging in OR Send an email request to assist@bsmail.in from your registered email address and quoting your cell phone number.


Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

First published: Wed, December 29, 2021. 6:53 PM IST

]]>